Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Insulet

Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022

5 Analysts Have This to Say About Insulet

5 Analysts Have This to Say About Insulet

Insulet (NASDAQ:PODD) has observed the following analyst ratings within the last quarter:

4 Analysts Have This to Say About Insulet

4 Analysts Have This to Say About Insulet

Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter:

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Dexcom Pops After Insulet Buyout Rumor Shakes Up Diabetes Stocks

Dexcom stock popped Tuesday after the diabetes devices company refuted rumors that it's in active negotiations to acquire any company.

Investors Business Daily

Looking Into Insulet's Return On Capital Employed

According to Benzinga Pro, during Q1, Insulet (NASDAQ:PODD) earned $27.80 million, a 4.79% increase from the preceding quarter. Insulet's sales decreased to $295.40 million, a 4.0% change since Q4.

How The Rumored Dexcom-Insulet Marriage Could Rock The Entire Diabetes Space

Dexcom stock yo-yoed Wednesday after a Tuesday dive on rumors it's in talks to acquire insulin pump-maker Insulet in a major diabetes deal.

Investors Business Daily

Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg

Dexcom Inc (NYSE:DXCM) is reportedly in talks to acquire medical-device company Insulet Corporation (NASDAQ: PODD) to create a giant in diabetes devices, according to people with knowledge of the matter. According to Bloomberg, talks between the companies are ongoing, and an agreement could be reached in the coming weeks. Discussions could still be delayed or fall…

inkl

Read news from The Economist, FT, and more,
with one subscription

Expert Ratings for Insulet

Expert Ratings for Insulet

Within the last quarter, Insulet (NASDAQ:PODD) has observed the following analyst ratings:

Insulet Q1 Earnings Beats Street View, Says Omnipod 5 Rollout Is 'Progressing Very Well'

Insulet Q1 Earnings Beats Street View, Says Omnipod 5 Rollout Is 'Progressing Very Well'

Insulet Corporation (NASDAQ:PODD) posted Q1 profits of $27.8 million, or an EPS of $0.40, beating the consensus of $0.23. Q1 sales increased 17.1% Y/Y, or 19.3% in constant currency, to $295.4 million, exceeding the guidance range of 13% to 16% in constant currency and the consensus of $288.18 million. “We are off…

Recap: Insulet Q1 Earnings

Recap: Insulet Q1 Earnings

Insulet (NASDAQ:PODD) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet beat estimated earnings by 73.91%, reporting an EPS of $0.4 versus an estimate of $0.23.

Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes

Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes

Insulet Corporation (NASDAQ:PODD) unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes patients. Paired with DexCom Inc's (NASDAQ:DXCM) G6 continuous glucose monitoring (CGM) system, Omnipod 5 is the first tubeless, wearable, automated insulin delivery system. Related: FDA Approves Insulet's Omnipod Automated Insulin Delivery System Patients…

Insulet Posts Street-Beating Q4 Earnings, Omnipod Revenues Up ~20%

Insulet Posts Street-Beating Q4 Earnings, Omnipod Revenues Up ~20%

Insulet Corp's (NASDAQ: PODD)

Recap: Insulet Q4 Earnings

Recap: Insulet Q4 Earnings

Insulet (NASDAQ:PODD) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet beat estimated earnings by 31.25%, reporting an EPS of $0.42 versus an estimate of $0.32.

Expert Ratings For Insulet

Expert Ratings For Insulet

Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter:

Get all your
news in one place.

100’s of premium titles.
One news app.

FDA Approves Insulet's Omnipod Automated Insulin Delivery System Patients Aged 6 Years & Above

Benzinga Pro's Top 5 Stocks To Watch For Friday, Jan. 28, 2022: PODD, KR, TEAM, GOOGL, SBUX

Today's 5 Stock Ideas: Insulet (PODD) - Shares up premarket. The company announced FDA clearance of its Omnipod 5 Automated Insulin Delivery System. Kroger (KR) - Shares down premarket. Citigroup downgraded

Organisations

Bank of America

B of A Securities

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

244,403 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play